Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):340-347. doi: 10.1007/s00259-017-3854-6. Epub 2017 Oct 16.

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.

Author information

1
Department of Radiology, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany. m.freitag@dkfz.de.
2
Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
3
Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.
4
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
5
Medical Image Computing Group, German Cancer Research Center, Heidelberg, Germany.
6
Department of Nuclear Medicine, Technical University Hospital Munich, Munich, Germany.
7
Department of Radiology, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany.
8
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
9
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.

Abstract

INTRODUCTION:

The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body 18F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients.

METHODS:

Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after 18F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUVmean-quantification was performed using a 3D-isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0).

RESULTS:

The examinations were well accepted by patients and comprised 1 h. SUVmean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of 18F-PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results.

CONCLUSIONS:

The presented 18F-PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.

KEYWORDS:

18F-PSMA-1007; 68Ga-PSMA-11; PET/MRI; PSMA; PSMA-PET; Prostate cancer

PMID:
29038888
DOI:
10.1007/s00259-017-3854-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center